These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33813435)

  • 61. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Regorafenib and trifluridine/tipiracil in real clinical practice.
    García-Beloso N; Romero-Ventosa EY; Gayoso-Rey M; López-López A; Robles-Torres D; de Castro NM; Piñeiro-Corrales G
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S367-S373. PubMed ID: 36510990
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.
    Paly VF; Dasari A; Hubbard J; Bekaii-Saab T; Padukkavidana T; Hernandez L
    J Comp Eff Res; 2024 Aug; 13(8):e240084. PubMed ID: 38976346
    [No Abstract]   [Full Text] [Related]  

  • 67. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
    Sousa MJ; Gomes I; Pereira TC; Magalhães J; Basto R; Paulo J; Jacinto P; Bonito N; Sousa G
    Cancer Treat Res Commun; 2022; 31():100531. PubMed ID: 35172243
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
    Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
    Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sequencing beyond the second-line setting in metastatic colorectal cancer.
    Grothey A; Marshall JL; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):1-19. PubMed ID: 31730588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
    Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
    Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
    Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
    ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
    Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J
    Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
    Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
    Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
    Oshima K; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Boku N
    PLoS One; 2022; 17(6):e0269115. PubMed ID: 35653412
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
    Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
    Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.
    Ottaiano A; Santorsola M; Ianniello M; Ceccarelli A; Casillo M; Sabbatino F; Petrillo N; Cascella M; Caraglia F; Picone C; Perri F; Sirica R; Zappavigna S; Nasti G; Savarese G; Caraglia M
    J Transl Med; 2024 Apr; 22(1):379. PubMed ID: 38650006
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
    Abrahao ABK; Ko YJ; Berry S; Chan KKW
    Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.